HK INNO.N
HK INNO.N
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Seoul, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.inno-n.com
Total Employee:
1001+
Status:
Active
Contact:
82 2 6740 2119
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Domain Not Resolving Apache Mobile Non Scaleable Content
Similar Organizations
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Palo Santo Fund
Palo Santo Fund is an investment fund that invests in psychedelic and healthcare industry.
Current Employees Featured
Official Site Inspections
http://www.inno-n.com Semrush global rank: 1.5 M Semrush visits lastest month: 17.91 K
- Host name: 139.150.80.195
- IP address: 139.150.80.195
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "HK inno.N"
HK inno.N
Inno.N is committed to the values of promoting the health of mankind and sustainability of the environment. The company practices these values based on the belief that it has a social …See details»
HK inno.N Corporation Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for HK inno.N Corporation of Cheongju, Chungbuk. Get the latest business insights from Dun & Bradstreet.See details»
inno.N Company Profile - Office Locations, Competitors ... - Craft
See insights on inno.N including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
HK inno.N - Crunchbase Investor Profile & Investments
HK inno.N acquired the South Korea rights for the GLP-1 drug from China's Sciwind.See details»
HK inno.N Corp. - Drug pipelines, Patents, Clinical trials - Synapse
Explore HK inno.N Corp. with its drug pipeline, therapeutic area, technology platform, 113 clinical trials, 9 news, and 24 literature, Disease Domain:Neoplasms, Endocrinology and Metabolic …See details»
Organization | Inno.N - Purdue University
Founded: Seoul Korea, Republic of (1984)Organization OverviewSee details»
Company Profile of HK inno.N Corporation - pharmasources.com
Building on this success, inno.N remains committed to growing into a global bio health company built on outstanding products and technologies that bring us closer to a healthier future.See details»
inno.N - Portfolio Company Profile, Executives and Private Equity …
See inno.N's complete profile, including its private equity owner and the number of its executive contacts in our database. inno.N, originally known as CJ HealthCare and a CJ Group …See details»
Kwak Dal-won - CEO of HK inno.N - koreawho.com
2 days ago Kwak Dal-won is the CEO and President of HK inno.N. After CJ Healthcare was acquired by Korea Kolmar, its name was changed to HK inno.N. HK inno.N aims to maximize …See details»
IN 114199 - AdisInsight
HK inno.N (formerly CJ Healthcare) is developing IN 114199, an ileal bile acid transporter (IBAT) inhibitor, for the treatment of constipation. IBAT isSee details»
HK INNO.N CORPORATION - FDA Site Profile
Jan 24, 2025 HK INNO.N CORPORATION - Cheongju, Korea (the Republic of) FDA Site Report FEI Number: 3022306074 Total Inspections: 1 Total 483s Issued: 1 Total Warning Letters …See details»
HK inno.N posts 88.2 billion won operating profit, up 34% from …
Feb 11, 2025 HK inno.N announced on the 11th that its operating profit on a separate basis was 88.2 billion won, which is a 33.8% increase compared to the previous year.See details»
IN-114199 - Drug Targets, Indications, Patents - Synapse
3 days ago IN-114199, Initially developed by HK inno.N Corp., Now, its global highest R&D status is Phase 1, Therapeutic Areas: Other Diseases, Active Indication: Constipation, Active …See details»
HK inno.N
HK inno.N introduces its products through a variety of channels such as overseas pharmaceutical exhibitions, export consultation meetings and international partnerships, etc., and contributes …See details»
HK inno.N
Jan 16, 2024 Geun Seog Song, vice president of R&D in HK inno.N explained, “we noted the value of cell and gene therapy, a representative player of the advanced therapy medicinal …See details»
IN-B00003 - Drug Targets, Indications, Patents - Synapse
Mar 20, 2025 IN-B00003, Initially developed by HK inno.N Corp., Now, its global highest R&D status is Discovery, Therapeutic Areas: Neoplasms, Active Indication: Neoplasms, Active ...See details»
HK inno.N
Inno.N, based on the values of creativity, reason, proactiveness and self-reliance, has established and hereby declare anti-corruption policies as follows as it seeks to contribute to a valuable, …See details»
HK inno.N, Hits Upper Limit on U.S. Phase 3 Success[K-Bio Pulse]
Apr 26, 2025 HK inno.N hit the upper limit after its gastroesophageal reflux disease (GERD) treatment K-CAB (Tegoprazan) showed outstanding results in its U.S. Phase 3 trial.See details»
IN-120190 - Drug Targets, Indications, Patents - Synapse
IN-120190, Initially developed by HK inno.N Corp., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms, Active Indication: Neoplasms ...See details»
IN-C011 - Drug Targets, Indications, Patents - Synapse
IN-C011, Initially developed by HK inno.N Corp., Now, its global highest R&D status is Pending, Therapeutic Areas: Endocrinology and Metabolic Disease.See details»